CORC

在结果中检索

CORC

浏览/检索结果: 共44条，第1-10条 帮助

已选(0)清除 条数/页：   排序方式：
Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients 期刊论文
CANCER MEDICINE, 2022
作者:  Hao, Yue;  Lin, Gen;  Xiang, Jing;  Wang, Wenxian;  Xu, Chunwei
收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23
Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial 期刊论文
BMC MEDICINE, 2022, 卷号: 20
作者:  Song, Zhengbo;  Lou, Guangyuan;  Wang, Yina;  Yang, Zhiping;  Wang, Wenxian
收藏  |  浏览/下载：13/0  |  提交时间：2022/12/23
Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer 期刊论文
JOURNAL OF ONCOLOGY, 2022, 卷号: 2022
作者:  Li, Yue;  Li, Chong;  Jiang, Ya;  Han, Xue;  Liu, Sisi
收藏  |  浏览/下载：14/0  |  提交时间：2022/12/23
Case Report: Hepatic Sarcoid-Like Reaction Associated With Checkpoint Inhibition in a NSCLC Patient and a Literature Review 期刊论文
FRONTIERS IN ONCOLOGY, 2022, 卷号: 12
作者:  Lin, Yuxin;  Zhu, Wei;  Wu, Bingchen;  Lan, Huiyin
收藏  |  浏览/下载：18/0  |  提交时间：2022/05/16
Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China 期刊论文
THORACIC CANCER, 2021
作者:  Shi, Yuequan;  Fang, Jian;  Zhou, Chengzhi;  Liu, Anwen;  Wang, Yan
收藏  |  浏览/下载：63/0  |  提交时间：2022/01/25
A Support Vector Machine Based on Liquid Immune Profiling Predicts Major Pathological Response to Chemotherapy Plus Anti-PD-1/PD-L1 as a Neoadjuvant Treatment for Patients With Resectable Non-Small Cell Lung Cancer 期刊论文
FRONTIERS IN IMMUNOLOGY, 2021, 卷号: 12
作者:  Peng, Jie;  Zou, Dan;  Han, Lijie;  Yin, Zuomin;  Hu, Xiao
收藏  |  浏览/下载：22/0  |  提交时间：2022/02/14
A new approach to produce IgG(4)-like bispecific antibodies 期刊论文
SCIENTIFIC REPORTS, 2021, 卷号: 11, 期号: 1, 页码: 12
作者:  Zhao, Caizhi;  Zhang, Wei;  Gong, Guihua;  Xie, Liping;  Wang, Ming-Wei
收藏  |  浏览/下载：23/0  |  提交时间：2021/11/04
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). 期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2021, 卷号: 39
作者:  Socinski, Mark A.;  Spira, Alexander I.;  Paz-Ares, Luis G.;  Reck, Martin;  Lu, Shun
收藏  |  浏览/下载：31/0  |  提交时间：2022/01/10
Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma 期刊论文
JOURNAL OF THORACIC DISEASE, 2021, 卷号: 13
作者:  Shen, Dijian;  Wang, Jiangfeng;  Wu, Jie;  Chen, Sheng;  Li, Jianqiang
收藏  |  浏览/下载：25/0  |  提交时间：2021/05/10
The safety and efficacy of neoadjuvant PD-1 inhibitor with chemotherapy for locally advanced esophageal squamous cell carcinoma 期刊论文
JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2021, 卷号: 12
作者:  Shen, Dijian;  Chen, Qixun;  Wu, Jie;  Li, Jianqiang;  Tao, Kaiyi
收藏  |  浏览/下载：36/0  |  提交时间：2021/04/26

©版权所有 ©2017 CSpace - Powered by CSpace